342 results about "Ribose" patented technology

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The invention discloses temozolomide derivatives or pharmaceutically acceptable salts, crystal forms and solvates, wherein the structure of the temozolomide derivatives is shown as a formula I in the specification. According to the temozolomide derivative disclosed by the invention, damage caused by repairing temozolomide by cells is prevented by inhibiting PARP1 protein, so that the purpose of improving the overall anti-glioblastoma effect is achieved. The invention further discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate to preparation of a PARP1 inhibitor. The invention also discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate in preparation of medicines for preventing and / or treating tumors. The invention also discloses a pharmaceutical composition, and the pharmaceutical composition takes a safe and effective amount of temozolomide derivative or pharmaceutically acceptable salt, crystal form and solvate as effective components or main effective components, and is prepared into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier.

The present disclosure provides linker compounds of Formula (I) or (II):pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

The invention discloses a low-temperature preservation method of a prepared meat product, and belongs to the technical field of food processing. In order to solve the technical problems that in the low-temperature storage process of the conditioned meat product, microorganism control is not thorough, secondary pollution and fat oxidation aggravation are caused by accumulation of high-oxygen conditioned packaging condensate water, and texture damage is caused by ultrahigh-pressure treatment, metal ion catalysis is blocked through phytic acid pretreatment, oxidation is inhibited through composite antioxidant vacuum rolling and kneading, and the quality of the conditioned meat product is improved. Gradient ultrahigh pressure destroys microbial structures in stages, citric acid and a D-ribose buffer solution block damaged thalli from repairing, a composite packaging bag is lined with a hygroscopic film and filled with high-oxygen mixed gas to maintain meat color and adsorb condensate water, and finally, the composite packaging bag is deeply frozen to form a microcrystalline structure and then transferred to an ice-temperature environment for storage. The method realizes microbial safety control under the condition of no chemical preservative, effectively maintains the cell integrity of meat products, reduces juice loss and fat oxidation, prolongs the shelf life and maintains the eating quality.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The preparation method of the locked nucleic acid intermediate D-ribofuranose derivative, provided by the invention, is simple in steps, stable in process, high in selectivity and easy for industrial production, and has a relatively good application prospect. According to the preparation method, the yield and the purity can be greatly improved, the economic cost is reduced, steps are shortened, multiple operation modes are simplified, the amount of organic waste liquid is remarkably reduced, materials and process conditions with safety risks are eliminated, operation with serious equipment loss is avoided, and the process conditions and the result are stable.

The invention relates to a plant having an increased proportion of edible biomass resulting from genetic modification of gene that encodes a poly(adenosine 5′-diphosphate (ADP)-Ribose) Polymerase (PARP) enzyme.

The invention provides a method for cultivating anti-aging glutinous highland barley, highland barley starch as well as a preparation method and application of the highland barley starch, and particularly relates to a method for improving the starch quality character of an existing high-quality glutinous highland barley variety, in particular to a method for cultivating anti-aging glutinous highland barley by utilizing a gene editing technology without exogenous DNA (Deoxyribose Nucleic Acid) integration. A method for fixed-point knockout of an SSIIa gene to cultivate an anti-aging glutinous highland barley new strain under the background of a "Zhengnongglutinous 232" variety comprises the following steps: providing an acceptor material derived from a highland barley variety "Zhengnongglutinous 232" with a glutinous character, and deleting a Wx gene function of the "Zhengnongglutinous 232"; the method comprises the following steps: assembling guide RNA (Ribonucleic Acid) designed aiming at an SSIIa gene and Cas9 protein in vitro to form a ribonucleoprotein RNP complex; introducing the RNP complex into cells of an acceptor material so as to enable Cas9 protein to generate double-chain breakage at a target site of the SSIIa gene; carrying out culture and plant regeneration on the introduced cells to obtain a T0-generation plant of which the SSIIa gene is edited; and screening plants with the function loss of the SSIIa gene, wherein the plants keep the glutinous character of adult agricultural glutinous 232.

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.

The present disclosure relates to biodegradable polymeric microspheres comprising a biodegradable polymer and an immunotherapeutic agent selected from the group consisting of a poly ADP ribose polymerase inhibitor (PARP inhibitor) and / or a Toll-like receptor (TLR) agonist, wherein (a) 50% of the total amount of the immunotherapeutic agent in the biodegradable polymer microspheres is released from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; (b) releasing the immunotherapeutic agent with the dry weight of 1 mg / g to 100 mg / g from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; or (c) satisfies both (a) and (b). Other aspects of the present disclosure relate to methods of using such microparticles and kits comprising such microparticles.

To provide a composition that exhibits excellent bacteriostatic performance.SOLUTION: A bacteriostatic composition comprises (A) melanoidin produced from at least one selected from xylose and ribose and at least one selected from phenylalanine and proline as a reaction substrate, and (B) a chelating agent. It is preferable that the chelating agent (B) is at least one selected from citric acid or a salt thereof and condensed phosphoric acid or a salt thereof. It is also preferable that the composition further contains at least one selected from organic acids or salts thereof other than the chelating agent. It is also preferable that the organic acid or a salt thereof is acetate.SELECTED DRAWING: None

The present disclosure provides compounds, in part, compounds having Formula (I) or Formula (II), and their use in the treatment of medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making the compounds of the present disclosure are provided. These compounds are envisaged to be modulators, e.g., inhibitors, of cyclic ADP ribohydrolase (CD38).

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

This invention belongs to the field of antitumor drug technology, specifically relating to PARP inhibitor-quinoline carboxylic acid coupled derivative compounds, their preparation methods, and uses. This invention synthesizes a novel polyADP-ribose polymerase (PARP) inhibitor derivative, the structure of which includes: a first structural unit with the clinical PARP inhibitor olaparib as the core backbone, a linker arm L, and a quinoline carboxylic acid fragment R; wherein the structural types and substituents of the linker arm L and the quinoline carboxylic acid fragment R are adjustable. This invention also provides a method for preparing the compound, which is characterized by simple steps, strong versatility, and ease of structural expansion, suitable for constructing compound libraries with different combinations of linker arms and different quinoline carboxylic acid fragments. The compound can be used to prepare drugs or drug compositions for inhibiting tumor cell proliferation and treating tumor-related diseases, showing excellent application prospects.

The application provides a double-stranded walking type DNA nanomachine and a preparation method and application thereof, and relates to the technical field of fluorescent analysis and detection.The double-stranded walking type DNA nanomachine for ctDNA fluorescent detection comprises a gold nanoparticle carrier, an anchor probe, a FAM fluorescent reporter probe, a double-stranded walking arm, a Cas12a protein and a crRNA to form a ribonucleoprotein complex.The walking arm of a conventional CRISPR / Cas12a nanomachine is a DNA single-stranded structure, which is easily cut in trans by activated Cas12a, thereby reducing the stability and sensitivity of the nanomachine.The application introduces a double-stranded DNA structure into the walking arm design to replace the conventional DNA single-stranded walking arm, constructs a double-stranded walking type three-dimensional DNA CRISPR / Cas12a nanomachine, effectively resists the reverse cutting of Cas12a on the walking arm, maintains the structural integrity and functional stability of the nanomachine, and greatly improves the detection sensitivity and specificity of lung cancer ctDNA, thereby having a good clinical application prospect.

To provide a food composition that does not contain animal-derived substances and that can be used as a food additive or flavoring to impart spice, umami, or meat seasoning to a food composition by utilizing fungi, yeast, and extracts of Ogataea pholymorpha. SOLUTION: The Ogataea polymorphic fungus yeast, extract, and biomass extract of the Ogataea polymorphic fungus of the present invention contain 0.03 to 3.1% w / w heme. They also contain 0.1 to 25% w / w amino acids. They also contain 0.1 to 2% w / w histidine. They are dissolved or formed by hydrolysis. The Ogataea polymorphic fungus of the present invention further contains proteins, amino acids, carbohydrates, and vitamins. They also contain glutathione. The present invention also relates to the production of recombinant heme proteins in methylotrophic yeast such as Ogataea polymorphic fungus. The Ogataea polymorphic fungus extract contains 0.007% or more 5' ribonucleotides. The 5' ribonucleotides are extracted from 5' GMP.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present application relates to ticagrelor intermediates and a preparation method thereof, wherein a halogenated group of compound VI is removed by a deacidifying agent to open a ring, process conditions are simple, and operation is easy; meanwhile, a chiral center in a molecule is constructed by using a transaminase to prepare compound VII from compound VI, conditions are more mild, chiral selectivity is better, raw material utilization is improved, chiral separation or chiral reduction process is avoided, and industrialized production is more beneficial. The disclosed technical scheme can be connected with a process for preparing compound VII from D-ribose as a starting material, forming a process for preparing target compound ticagrelor intermediate compound VII from compound I (D-ribose) as a raw material, synthesizing compound II by reacting with methanol, then synthesizing compound III by sulfonylization of compound II, then synthesizing compound IV by halogen substitution of compound III, and further opening a ring, closing a ring, and catalyzing by a transaminase.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a fat component for treating Alzheimer's disease and a preparation method of the fat component. The fat component is prepared from the following raw materials in parts by weight: medium-chain triglyceride, starch sugar, silicon dioxide, sodium caseinate, starch sodium octenylsuccinate, mono-glycerol fatty acid ester, diglycerol fatty acid ester and potassium hydroxide. And a neuroprotective nutrient combination. According to the invention, the medium-chain triglyceride capable of supplying energy quickly is creatively combined with the nerve protection nutrient with a specific mechanism. The medium-chain triglyceride provides efficient ketone energy; magnesium citrate stabilizes the excitability of neurons; the nicotinamide ribose supports cell energy metabolism; the omega-3 fatty acid plays roles in resisting inflammation and repairing nerve cell membranes. The four components provide protection from energy supply, neuron stabilization, metabolism support and structure repair, and bring better neurological function prognosis while controlling the Alzheimer's disease.

The application belongs to the technical field of biological breeding, and particularly relates to application of D-ribose in improving plant salt stress resistance. The application provides application of D-ribose in improving plant salt stress resistance. As an important plant metabolite, D-ribose plays a key role in the growth and development stage of plants. Under salt stress conditions, application of D-ribose can not only promote the growth of plant taproot, plant height and leaf, reduce the inhibitory effect of salt stress on crop growth, but also has a protective effect on flowering and seed production of later plants. The application method is simple, and the use effect is remarkable.

The invention particularly relates to 4 '-thiosugar and a preparation method thereof. The preparation method comprises the following steps: taking D-ribose as a raw material, firstly carrying out methylation protection on C1-site hydroxyl, and then carrying out benzylation protection on other hydroxyl; the preparation method comprises the following steps: firstly, carrying out hydrolysis on a glucosidic bond at a C1 site, carrying out reduction through hydroboron to obtain open-loop ribitol (formula V), carrying out sulfonic acid esterification and bromination substitution on hydroxyl of the ribitol, forming a sulfur bridge bond by taking sodium sulfide as a nucleophilic reagent to obtain benzyl-protected thiosugar, oxidizing a thioether bond into sulfoxide, rearranging to obtain acetoxy thioether, and carrying out debenzylation reaction and hydroxybenzoylation reaction to obtain the high-purity acetoxy thioether. According to the present invention, the multi-step intermediate reaction only needs simple purification, the key intermediate can be obtained through recrystallization, the method is simple, the yield is high, the amplification production is convenient, and the obtained 4 '-thiosugar as the basic sugar can participate in the reaction with a variety of basic groups to form the sulfur-containing nucleoside so as to provide the good foundation for the subsequent drug development or activity screening.

This invention relates to lipid nanoparticles for in vivo skin gene editing in fish and their applications, belonging to the field of fish gene editing technology. The lipid nanoparticles for in vivo skin gene editing in fish comprise: a gene editing element and a lipid layer, wherein the lipid layer coats the surface of the gene editing element; the gene editing element is a CRISPR / Cas9 ribonucleoprotein complex or a nucleic acid encoding the complex; the lipid nanoparticle carrier comprises ionizable cationic lipids, auxiliary lipids, cholesterol, polyethylene glycol-modified lipids, and permanently cationic lipids, and by molar weight, the proportions are 15 parts ionizable cationic lipids, 25-30 parts auxiliary lipids, 30 parts cholesterol, 3 parts polyethylene glycol-modified lipids, and 7 parts permanently cationic lipids. The formulation of this invention is highly targeted, has high editing efficiency, is simple and safe to operate, and has broad application prospects.

The present disclosure relates to a novel system for the generation and use of hybrid alpha-pseudoviruses against ribose viruses. A hybrid ribose virus-alpha-pseudovirus (HRAP) presents a novel particle having an RNA genome derived from an alphavirus and a structural protein of a virus in the ribose virus field. The HRAP particle is formed by assembling structural proteins crossing different riboviridae and can be used for vaccine development, antiviral drug screening, neutralization test, treatment or immune response starting and the like.

The utility model relates to the field of D-ribose separation and purification equipment, and discloses D-ribose separation and purification equipment which comprises a collection box, a separation mechanism is arranged in the collection box, a cleaning mechanism is arranged at the top of the collection box, and a base is arranged at the bottom of the collection box. The separating mechanism comprises a fixing frame, a positioning frame, a connecting block, a filter screen and a hydraulic rod, the output end of the hydraulic rod is fixedly connected with the connecting block, and the connecting block sequentially penetrates through the collecting box and the fixing frame and is fixedly connected with the positioning frame. D-ribose can fall on a filter screen, the output end of a hydraulic rod drives a connecting block to move, a positioning frame can be driven to move, the filter screen can be moved, screening of the D-ribose is facilitated, large granular D-ribose can be separated from powdery D-ribose, and subsequent processing is facilitated.

The invention belongs to the technical field of biological medicine, and particularly relates to an RNA balling modification method. According to the invention, a novel imidazole derivative 1-azio-15-(1H-midazol-1-yl)-3, 6, 9, 12-tetroxapetadecan-15-one is synthesized, a brand new sRNA synthesis modification system is developed on the basis of the compound, the compound is modified by a RNA ribose two-position hydroxyl group, the hydrolysis resistance of RNA is improved, the modified RNA forms spherical particles by virtue of a microfluidic system, and the hydrolysis resistance of the RNA is improved. Meanwhile, the spherical structure is stabilized through connection of the lipid compound, so that the diameter of the synthesized spherical RNA is remarkably reduced compared with that before balling, the stability is greatly improved, a solution is provided for the defects of poor RNA delivery stability and dependence on a carrier in the prior art, and a new strategy is provided for RNA vaccine delivery.

A tricyclic heterocyclic compound, its preparation, and its applications are disclosed. Specifically, a tricyclic heterocyclic compound as shown in Formula IA or a pharmaceutically acceptable salt thereof is provided. This tricyclic heterocyclic compound exhibits good inhibitory activity against poly(ADP-ribose) polymerase and can significantly inhibit the growth of NCI-H1373 human lung adenocarcinoma cells. It can be used as a drug for the treatment and / or prevention of abnormal proliferative diseases or other diseases related to the targets that this series of compounds targets; for example, cancer.

A method for treating a homologous recombination (HR)-deficient cancer, a homologous recombination (HR)-proficient cancer or a cancer that is resistant to DNA repair and DNA damage response (DDR) inhibitor therapy, such as Poly (ADP-Ribose) Polymerase (PARP) inhibitor therapy, is provided, the method comprising administering to a subject an RNA-binding motif protein 39 (RBM39) degrader, such as an aryl sulfonamide. A DDR inhibitor, such as a PARP inhibitor, may also be administered. A composition comprising a RBM39 degrader, such as an aryl sulfonamide, e.g., E7820 or Compound A, and a DDR inhibitor, such as a PARP inhibitor, is also provided.

The application discloses a method for detecting glutathione by using manganese-based chiral nanomaterials, and belongs to the field of chemical engineering, specifically to the field of analytical chemistry technology. The method comprises the following steps: taking a dispersion liquid of manganese-based chiral nanomaterials as a detection reagent, mixing the detection reagent with a sample containing glutathione to be detected, and comparing a circular dichroism spectrum signal with a standard curve to obtain the concentration of the sample containing glutathione to be detected; wherein a chiral ligand of the manganese-based chiral nanomaterials is ribose. Based on the circular dichroism spectrum detection, the detection wavelength band used is in the visible light region, is not easy to be disturbed, is sensitive, and the resolution can reach 3 muM, and the detection limit is 1.5 muM, which has important significance and value for promoting the development of the fields of optics, life science, medicine and the like.